124 related articles for article (PubMed ID: 35933981)
1. A Gene Signature Comprising Seven Pyroptosis-Related Genes Predicts Prognosis in Pediatric Patients with Acute Myeloid Leukemia.
He X; Jiang Y; Yu X; He F; Gao H
Acta Haematol; 2022; 145(6):627-641. PubMed ID: 35933981
[TBL] [Abstract][Full Text] [Related]
2. Endoplasmic reticulum stress-related signature predicts prognosis and immune infiltration analysis in acute myeloid leukemia.
Dong L; Wang H; Miao Z; Yu Y; Gai D; Zhang G; Ge L; Shen X
Hematology; 2023 Dec; 28(1):2246268. PubMed ID: 37589214
[TBL] [Abstract][Full Text] [Related]
3. Construction of a Pyroptosis-Related Signature for Prognostic Prediction and Characterization of Immune Microenvironment in Acute Myelogenous Leukemia.
Liu S; Luo D; Luo J; Liang H; Zhi Y; Wang D; Xu N
Int J Gen Med; 2022; 15():2913-2927. PubMed ID: 35308573
[TBL] [Abstract][Full Text] [Related]
4. A Novel Defined Pyroptosis-Related Gene Signature for the Prognosis of Acute Myeloid Leukemia.
Huang K; Xie L; Wang F
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553549
[TBL] [Abstract][Full Text] [Related]
5. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
Staffas A; Kanduri M; Hovland R; Rosenquist R; Ommen HB; Abrahamsson J; Forestier E; Jahnukainen K; Jónsson ÓG; Zeller B; Palle J; Lönnerholm G; Hasle H; Palmqvist L; Ehrencrona H;
Blood; 2011 Nov; 118(22):5905-13. PubMed ID: 21967978
[TBL] [Abstract][Full Text] [Related]
6. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
7. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
9. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A; Taki T; Koga D; Tabuchi K; Tawa A; Hanada R; Tsuchida M; Horibe K; Tsukimoto I; Adachi S; Kojima S; Hayashi Y
Int J Hematol; 2012 Oct; 96(4):469-76. PubMed ID: 22915059
[TBL] [Abstract][Full Text] [Related]
10. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a risk model correlated with metabolism based on RNA-binding proteins associated with cell pyroptosis in acute myeloid leukemia.
Bin T; Lin C; Liu FJ; Wang Y; Xu XJ; Lin DJ; Tang J; Lu B
Front Oncol; 2022; 12():1059978. PubMed ID: 36465357
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of a pyroptosis-related gene signature of clinical and biological value in acute myeloid leukaemia.
Shao R; Wang H; Wang J; Lu S; He R; Lu Y
Int Immunopharmacol; 2022 Jul; 108():108802. PubMed ID: 35569433
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
[TBL] [Abstract][Full Text] [Related]
14. Integrated bioinformatic analysis of mitochondrial metabolism-related genes in acute myeloid leukemia.
Tong X; Zhou F
Front Immunol; 2023; 14():1120670. PubMed ID: 37138869
[TBL] [Abstract][Full Text] [Related]
15. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
[TBL] [Abstract][Full Text] [Related]
16. CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia.
Liao XY; Fang JP; Zhou DH; Qiu KY
Hematol Oncol; 2022 Apr; 40(2):258-268. PubMed ID: 34816468
[TBL] [Abstract][Full Text] [Related]
17. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
19. A Novel 85-Gene Expression Signature Predicts Unfavorable Prognosis in Acute Myeloid Leukemia.
Lai Y; Sheng L; Wang J; Zhou M; OuYang G
Technol Cancer Res Treat; 2021; 20():15330338211004933. PubMed ID: 33784904
[TBL] [Abstract][Full Text] [Related]
20. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
